James F. Howard Jr., MD, FAAN / Nicholas J. Silvestri, MD, FAAN - Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.

Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

SupportThis activity is supported by an educational grant from argenx US, Inc.

Disclosure information is available at the beginning of the video presentation.